The Effects of Glucagon on Hepatic Metabolism

Obesity Clinical Trial

Official title: The Effects of Glucagon on Hepatic Metabolism

Status Recruiting

Clinical Trial Summary

Whether impaired postprandial glucagon suppression in prediabetes and T2DM is an attempt to overcome resistance to glucagon's actions on hepatic AA catabolism, a defect in α-cell function, or a combination of both are important, unanswered questions. NAFLD is associated with T2DM risk and impaired insulin action. Unfortunately, it is unclear if glucagon resistance is caused by obesity, hepatic steatosis or both. The experiments outlined will determine if glucagon's actions on hepatic amino acid catabolism and EGP interact with hepatic lipid metabolism in lean and obese subjects with and without T2DM (and with varying degrees of hepatic steatosis).

Clinical Trial Description

T2DM and prediabetes are characterized by abnormal post-prandial suppression of glucagon, which contributes to postprandial hyperglycemia by increasing EGP. Although these effects are magnified by decreased and delayed insulin secretion, they are also apparent when insulin secretion is intact. In rodents, altered glucagon signaling changes α-cell function and mass - an effect mediated by changes in circulating AA concentrations. Are the elevated concentrations of branched-chain AA and other AA metabolites in T2DM a cause or an effect of global α-cell dysfunction? Could altered glucagon signaling precipitate a vicious cycle resulting in T2DM? ;

Related Conditions & MeSH terms

• NAFLD
• Obesity

• NCT number: NCT05500586
• Study type: Interventional
• Source: Mayo Clinic
• Contact: Jeanette Laugen
• Phone: 5072558110
• Email: Laugen.Jeanette@mayo.edu
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: October 20, 2022
• Completion date: December 31, 2025